Samartzis and co-investigators reported that PI3K/AKT-pathway activation is also a crucial mechanism in ARID1A-mutated cancers and, consequently, ARID1A-deficient tumors show preclinical sensitivity to treatment with PI3K/Akt/mTor pathway inhibitors [38]. This evidence concerns the gene PIK3CA and cancer.